| アブストラクト | PURPOSE: Cetuximab sarotalocan is an innovative photoimmunotherapy agent for cancer treatment, with an unclear safety profile. We analysed the clinical adverse event profile of cetuximab sarotalocan in photoimmunotherapy. METHODS: In this retrospective study, we analysed real-world clinical data of patients with head and neck cancer from the Japanese Adverse Drug Event Report database. Patient demographics, as well as the nature of adverse events and their outcomes and co-occurrences, were analysed. RESULTS: Cetuximab sarotalocan adverse event reports (n = 227) predominantly included older male patients. The most frequent adverse event was laryngeal oedema, followed by upper respiratory and oral complications. Recovery rates were high for laryngeal oedema and tongue-related adverse events but poor for fistula-related complications. Co-occurrence was found between different adverse events, particularly laryngeal oedema and dysphagia. CONCLUSION: The described safety profile of cetuximab sarotalocan in photoimmunotherapy offers insights for its proper use as well as baseline data for the development and improvement of cancer photoimmunotherapy. |
|---|
| 投稿者 | Ueta, Shiho; Niimura, Takahiro; Fujino, Sakura; Goda, Mitsuhiro; Ishida, Tomoaki; Nawa, Hideki; Kawata, Emika; Tsujinaka, Kaito; Kawada, Kei; Miyata, Koji; Horikawa, Io; Aizawa, Fuka; Yagi, Kenta; Chuma, Masayuki; Izawa-Ishizawa, Yuki; Ishizawa, Keisuke |
|---|
| 組織名 | Department of Clinical Pharmacology and Therapeutics, Tokushima University;Graduate School of Biomedical Sciences, 3-18-15 Kuramoto, Tokushima, 770-8503,;Japan.;Japan. niimura@tokushima-u.ac.jp.;Department of Clinical and Translational Science, Tokushima University Hospital,;Tokushima, Japan. niimura@tokushima-u.ac.jp.;Department of Clinical Pharmacology and Therapeutics, Graduate School of;Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.;Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences,;Nagoya City University, Nagoya, Japan.;Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri;University, Tokushima, Japan.;Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.;Tokushima, Japan.;Department of Pharmacy, Shimane University Hospital, Shimane, Japan.;Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University,;Asahikawa, Japan.;Department of Health and Nutrition, Faculty of Human Life Science, Shikoku;Department of Community Healthcare Pharmacy, Tokushima University Graduate School;of Biomedical Sciences, Tokushima, Japan. |
|---|
